Next Article in Journal
Advances in Proteomic Techniques for Cytokine Analysis: Focus on Melanoma Research
Next Article in Special Issue
Role of Stem Cells in Pathophysiology and Therapy of Spondyloarthropathies—New Therapeutic Possibilities?
Previous Article in Journal
Effect of Guar Gum with Sorbitol Coating on the Properties and Oil Absorption of French Fries
Previous Article in Special Issue
Nitric Oxide Mediates Crosstalk between Interleukin 1β and WNT Signaling in Primary Human Chondrocytes by Reducing DKK1 and FRZB Expression
Article Menu
Issue 12 (December) cover image

Export Article

Open AccessArticle
Int. J. Mol. Sci. 2017, 18(12), 2696; https://doi.org/10.3390/ijms18122696

Clodronate as a Therapeutic Strategy against Osteoarthritis

1
Internal Medicine, Section D, Department of Medicine, University of Verona, 37134 Verona, Italy
2
Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, 37134 Verona, Italy
3
Biocrystallography Lab, Department of Biotechnology, University of Verona, 37134 Verona, Italy
*
Author to whom correspondence should be addressed.
Received: 16 November 2017 / Revised: 4 December 2017 / Accepted: 8 December 2017 / Published: 13 December 2017
(This article belongs to the Special Issue Research of Pathogenesis and Novel Therapeutics in Arthritis)
View Full-Text   |   Download PDF [1280 KB, uploaded 13 December 2017]   |  

Abstract

Osteoarthritis (OA), the most prevalent musculoskeletal pathology, is mainly characterized by the progressive degradation of articular cartilage due to an imbalance between anabolic and catabolic processes. Consequently, OA has been associated with defects in the chondrocitic differentiation of progenitor stem cells (PSCs). In addition, SOX9 is the transcription factor responsible for PSCs chondrogenic commitment. To evaluate the effects of the non-amino bisphosphonate clodronate in OA patients we investigated SOX9 gene expression in circulating progenitor cells (CPCs) and in an in vitro OA model. We evaluated pain intensity, mental and physical performance in OA patients, as well as serum biomarkers related to bone metabolism. In addition, in order to improve therapeutic strategies, we assayed nanoparticle-embedded clodronate (NPs-clo) in an in vitro model of chondrogenic differentiation. Our data showed upregulation of SOX9 gene expression upon treatment, suggesting an increase in chondrocytic commitment. Clodronate also reduced osteoarticular pain and improved mental and physical performance in patients. Furthermore, NPs-clo stimulated SOX9 expression more efficaciously than clodronate alone. Clodronate may therefore be considered a good therapeutic tool against OA; its formulation in nanoparticles may represent a promising challenge to counteract cartilage degeneration. View Full-Text
Keywords: clodronate; gene expression; osteoarthritis; progenitor cells; SOX9 clodronate; gene expression; osteoarthritis; progenitor cells; SOX9
Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Valenti, M.T.; Mottes, M.; Biotti, A.; Perduca, M.; Pisani, A.; Bovi, M.; Deiana, M.; Cheri, S.; Dalle Carbonare, L. Clodronate as a Therapeutic Strategy against Osteoarthritis. Int. J. Mol. Sci. 2017, 18, 2696.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top